BACKGROUND: @entity239 is a chronic condition of unknown aetiology characterised by @entity4512 that often co-exists with @entity25 , @entity73 and @entity1295 . @entity1 often report high disability levels and poor quality of life. Since there is no specific treatment that alters the pathogenesis of FM, drug therapy focuses on @entity158 reduction and improvement of other bothersome symptoms. OBJECTIVES: The objective of this review was to assess the effectiveness and safety of @entity1154 oxidase inhibitors (MAOIs) in the treatment of @entity239 . SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2010, Issue 10), MEDLINE (1966 to November 2010), EMBASE (1980 to November 2010) and the reference lists of reviewed articles. SELECTION CRITERIA: We selected all randomised, double-blind trials of MAOIs used for the treatment of @entity158 in adult @entity1 . DATA COLLECTION AND ANALYSIS: Two authors assessed risk of bias and extracted data independently onto a specially designed pro forma and a third review author cross-checked them. MAIN RESULTS: We included two studies of inconsistent risk of bias with a total of 230 @entity1 diagnosed with FM. We evaluated two MAOIs: @entity69870 and @entity13079 . @entity69870 showed statistically significant results compared with placebo for several outcomes ( @entity158 , tender points and overall assessment by the @entity1 and the physician), whereas @entity13079 did not show statistically significant differences between groups. Pooled results of the two studies displayed a modest effect size in @entity158 (mean difference (MD) -1.45 (121 @entity1 ; 95% confidence interval (CI) -2.71 to -0.20; number needed to treat (NNT) 2 (95% CI 1 to 12); I(2) = 59%)), implying a @entity922 ( @entity922 ) and a small effect on tender points (standardised mean difference (SMD) -0.36 (121 @entity1 ; 95% CI -0.72 to -0.00; I(2) = 31%)). No effect was seen on global assessment by @entity1 . Physical function and @entity25 were not measured. The most frequent adverse events were @entity390 and @entity391 , with statistically significant differences between groups (risk ratio (RR) 7.82 (89 @entity1 ; 95% CI 1.02 to 59.97; NNT 7 (95% CI 4 to 33)). AUTHORS' CONCLUSIONS: Data suggest that the effectiveness of MAOIs for the treatment of FM symptoms is limited. Although we observed a moderate effect size on @entity158 and a small one on tender points, these results should be taken with caution as they are only based on two studies with a small number of @entity1 and inconsistent risk of bias among them.

@entity1154 oxidase inhibitors (MAOIs) for XXXX syndrome.

@entity4512 :: ('MESH:D059352', 'Disease') :: ['musculoskeletal pain'] @entity1 :: ('9606', 'Species') :: ['participants', 'Patients', 'patients', 'patient'] @entity239 :: ('MESH:D005356', 'Disease') :: ['FM syndrome', 'Fibromyalgia (FM) syndrome'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity69870 :: ('MESH:C009830', 'Chemical') :: ['pirlindole', 'Pirlindole'] @entity73 :: ('MESH:D003072', 'Disease') :: ['cognitive dysfunction'] @entity13079 :: ('MESH:D020912', 'Chemical') :: ['moclobemide'] @entity1295 :: ('MESH:D005221', 'Disease') :: ['fatigue'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain', 'FM pain'] @entity1154 :: ('CHEBI:25375', 'Chemical') :: ['monoamine'] @entity25 :: ('MESH:D012893', 'Disease') :: ['sleep disturbance'] @entity922 :: ('MESH:D013568', 'Disease') :: ['minimal clinically important difference', 'MCID']
@entity239 :: (MESH:D005356,Disease) :: ['fibromyalgia']
